Skip to main content

Advertisement

Table 6 Incremental cost-effectiveness ratios, healthcare perspective, 0 to 6 months

From: Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial

  Incremental cost Incremental effect ICER
Mean; (95% bootstrap CI) Mean; (95% bootstrap CI)
CBT versus TAU
Completers ( N =152)        
QALY (EQ-5D) -1,577.6 -2,601.8 -553.4 0.01 -0.00 0.03 CBT dominant
EQ VAS -1,583.8 -2,606.9 -560.7 6.19 3.63 8.75 CBT dominant
ITT ( N =168)        
QALY (EQ-5D) -1,632.6 -2,744.6 -520.7 0.02 -0.00 0.03 CBT dominant
EQ VAS -1,635.0 -2,747.6 -522.3 6.33 3.59 9.07 CBT dominant
PPA ( N =154)        
QALY (EQ-5D) -1,773.5 -2,924.9 -622.1 0.02 -0.00 0.03 CBT dominant
EQ VAS -1,775.1 -2,927.6 -622.7 6.58 3.83 9.33 CBT dominant
CBT versus RPT
Completers ( N =152)        
QALY (EQ-5D) -1,866.8 -2,917.6 -816.0 0.01 -0.00 0.03 CBT dominant
EQ VAS -1,870.8 -2,921.6 -819.9 3.52 1.13 5.91 CBT dominant
ITT ( N =168)        
QALY (EQ-5D) -1,804.0 -2,786.7 -821.3 0.01 -0.00 0.03 CBT dominant
EQ VAS -1,805.4 -2,788.6 -822.2 3.61 1.08 6.15 CBT dominant
PPA ( N =154)        
QALY (EQ-5D) -1,972.8 -3,008.2 -937.5 0.01 -0.00 0.03 CBT dominant
EQ VAS -1,973.7 -3,011.3 -936.1 3.93 1.35 6.52 CBT dominant
RPT versus TAU
Completers ( N =152)        
QALY (EQ-5D) 289.2 -858.1 1,436.5 -0.00 -0.02 0.01 TAU dominant
EQ VAS 287.0 -857.3 1,431.2 2.67 0.55 4.79 107
ITT ( N =168)        
QALY (EQ-5D) 171.4 -1,037.3 1,380.0 0.00 -0.01 0.02 98,434
EQ VAS 170.4 -1,037.1 1,377.9 2.72 0.42 5.02 63
PPA ( N =154)        
QALY (EQ-5D) 199.3 -1,023.0 1,421.6 0.00 -0.01 0.02 107,697
EQ VAS 198.6 -1,022.6 1,419.7 2.65 0.35 4.94 75